Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

Aurelien Lathuiliere, Remi Vernet, Emily Charrier, Muriel Urwyler, Olivier Von Rohr, Marie-Claude Belkouch, Valentin Saingier, Thomas Bouvarel, Davy Guillarme, Adrien Engel, Patrick Salmon, Thomas Laumonier, Julien Grogg, and Nicolas Mach

Correspondence: aurelien.lathuiliere@unige.ch
https://doi.org/10.1016/j.omtm.2023.101130

(Molecular Therapy: Methods & Clinical Development 26, 441–458; September 2022)

In the originally published version of this article, the plasma concentration of anti-CD20 was provided in pg/mL in the text and in the graph in Figure 6D. After verifying the source data, the unit has been replaced by ng/mL in both the text and the figure. This has been corrected online.

The authors apologize for this error and any confusion it may have caused.

Figure 6D. Novel immortalized myoblasts can be used for the continuous delivery of complex therapeutic macromolecules with preserved functionality (original)

Figure 6D. Novel immortalized myoblasts can be used for the continuous delivery of complex therapeutic macromolecules with preserved functionality (corrected)